Protein C News and Research

RSS

Genetic cause of progressive hearing loss discovered

A team led by scientists from The Scripps Research Institute has discovered a genetic cause of progressive hearing loss. The findings will help scientists better understand the nature of age-related decline in hearing and may lead to new therapies to prevent or treat the condition.

4 Sep 2009

Type 2 diabetic people not consuming healthy diets

People with type 2 diabetes are not consuming sufficiently healthy diets and could benefit from ongoing nutritional education and counseling, according to a new study by researchers at Wake Forest University School of Medicine and colleagues.

4 Sep 2009

ROS in cells contributes to aging

With all the hype about beneficial antioxidants in everything from face cream to cereal bars, you'd think their targets---oxygen radicals---must be up to no good. It's true, the buildup of oxygen radicals and other reactive oxygen species (ROS) in cells contributes to aging and possibly to diseases such as cancer and Alzheimer's.

3 Sep 2009

RanBP9 protein targeted for developing new Alzheimer's drugs

"N60" might not be the first thing that comes to mind when people think of Alzheimer's disease, but thanks to researchers from the United States, South Korea and France, this might change. That's because these researchers have found that the N60 section of a protein called "RanBP9" might be the key that unlocks an entirely new class of Alzheimer's drugs, and with them, hope. In a research report published online in The FASEB Journal, these scientists describe how the N60 fragment of the RanBP9 protein increases the production of the amyloid beta protein, which is present in excessive amounts in the brains of people with Alzheimer's disease.

3 Sep 2009

Optimized turmeric extracts may prevent memory loss

scientists with HerbalScience Group LLC, working with researchers from other organizations and medical institutions, conducted an in-depth study of optimized turmeric extracts, demonstrating that key bioactives in the botanical extracts inhibit aggregation and release of amyloid, a protein fragment considered a prime causal suspect in Alzheimer's disease.

3 Sep 2009

THNN's Vice President to supervise the clinical research applications of SUPER MEAL RX

THNN Inc. (Transformation Health Nutrition Naturals Inc.) enthusiastically announces the appointment of Dr. Thoger Malmstrom to the position of Vice President for Nutritional Wellness Applications.

3 Sep 2009

New probe for identifying chemical process affected proteins functions like GPS

Scientists in Michigan are reporting the development of a powerful new probe for identifying proteins affected by a key chemical process important in aging and disease. The probe works like a GPS or navigation system for finding these proteins in cells. It could lead to new insights into disease processes and identify new targets for disease treatments, the researchers say. Their study is scheduled for the Sept. 18 issue of ACS Chemical Biology, a monthly journal.

3 Sep 2009

Clinical research paper on 2D gel electrophoresis for identifying protein biomarkers

Transgenomic, Inc. and Power3 Medical Products, Inc. (OTC Bulletin Board: PWRM) today announced the advance on-line publication of a clinical research paper entitled "Abnormal Serum Concentrations of Proteins in Parkinson's Disease" in the scientific journal Biochemical and Biophysical Research Communications.

3 Sep 2009

Strelitz Diabetes Center awarded a two-year grant for 12-LO research

Scientists at Eastern Virginia Medical School's Strelitz Diabetes Center have been awarded a two-year grant totaling $472,683 by the Juvenile Diabetes Research Foundation (JDRF).

3 Sep 2009

FDA's Oncologic Drugs Advisory Committee votes in favor of FOLOTYN NDA

Allos Therapeutics, Inc. (Nasdaq: ALTH) today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 10-4 that the response rate and duration of response observed with FOLOTYNTM (pralatrexate) are reasonably likely to predict clinical benefit in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).

3 Sep 2009

Researchers to analyse nanoparticles

Researchers at Swansea University's Centre for NanoHealth have been awarded £1 million by the Research Councils' Nanoscience through Engineering to Application cross-council programme, led by the Engineering and Physical Science Research Council (EPSRC), to analyse the levels at which nanoparticles can be deemed safe within cells.

3 Sep 2009

Yale University awarded $36 million ARRA funds for over 100 research projects

Faculty at Yale University have been awarded over 100 research grants totaling $36 million since February 2009, when the federal stimulus package was signed into law. Known as the American Recovery and Revitalization Act of 2009 (ARRA), the law aims to reinvigorate the economy and lay the foundation for long-term economic recovery by increasing investments in infrastructure, education, the environment and scientific research.

3 Sep 2009

New target for cancer cure identified

Researchers Dr. Marc Therrien at the Institute for Research in Immunology and Cancer (IRIC) of the Universit- de Montr-al, and Dr. Frank Sicheri, at the Samuel Lunenfeld Research Institute of Mount Sinai Hospital in Toronto, have discovered a new target that may be instrumental in the development of new, more effective cancer therapies.

3 Sep 2009

Scientists demonstrate the link between cancer and diesel fumes

Scientists here are the first to demonstrate that the link between diesel fume exposure and cancer lies in the ability of diesel exhaust to induce the growth of new blood vessels that serve as a food supply for solid tumors.

2 Sep 2009

Phase 1 single dose clinical trial of Acceleron Pharma's ACE-031 increases lean body mass

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, and muscle, today announced preliminary results from the ACE-031 Phase 1 single dose clinical trial indicating that ACE-031 was safe and well-tolerated at all dose levels and increased lean body mass.

2 Sep 2009

Selexis SA and NKT Therapeutics sign research services agreement

Selexis SA ("Selexis") and NKT Therapeutics, Inc. ("NKTT") announce today that they have entered into a research services agreement whereby Selexis will screen antibody variants and generate high performance CHO-based production cell lines using their novel platform named INTEGRA-D2M(TM).

2 Sep 2009

Gene causing periodontitis, rheumatoid arthritis and osteoporosis identified

Investigators at Hospital for Special Surgery, collaborating with researchers from other institutions, have contributed to the discovery that a gene called interferon regulator factor-8 (IRF-8) is involved in the development of diseases such as periodontitis (gum disease), rheumatoid arthritis and osteoporosis. The study, which will be published online August 30, ahead of print, in the journal Nature Medicine, could lead to new treatments in the future.

2 Sep 2009

TRAF6 protein plays a role in cell growth and carcinogenesis, says researchers

The mainstay immune system protein TRAF6 plays an unexpected, key role activating a cell signaling molecule that in mutant form is associated with cancer growth, researchers at The University of Texas M. D. Anderson Cancer Center report in the Aug. 28 edition of Science.

2 Sep 2009

LINGO1 variant responsible for essential tremors and Parkinson's disease

Researchers at the Mayo Clinic campus in Florida and their collaborators worldwide have discovered that a single gene promotes development of essential tremor in some patients and Parkinson's disease in others.

2 Sep 2009

Research on Ewing's sarcoma could lead to drugs for patients who do not respond to chemotherapy

Researchers at Huntsman Cancer Institute (HCI) at the University of Utah have shed new light on Ewing's sarcoma, an often deadly bone cancer that typically afflicts children and young adults. Their research shows that patients with poor outcomes have tumors with high levels of a protein known as GSTM4, which may suppress the effects of chemotherapy.

2 Sep 2009